June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Risk factors for disc haemorrhages in the United Kingdom Glaucoma Treatment Study
Author Affiliations & Notes
  • Jibran Mohamed-Noriega
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
    Oftalmología, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
  • Soledad Aguilar Munoa
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Georgios Lazaridis
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • David F Garway-Heath
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships   Jibran Mohamed-Noriega, None; Soledad Aguilar Munoa, None; Georgios Lazaridis, Santen (F); David Garway-Heath, Aerie (C), Alcon (C), Alcon research institute (F), Allergan (C), Bausch & Lomb (C), Heidelberg Engineering (F), Pfizer (C), Pfizer (F), Quark (C), Quethera (C), Santen (C), Santhera (C), Topcon (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3535. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jibran Mohamed-Noriega, Soledad Aguilar Munoa, Georgios Lazaridis, David F Garway-Heath; Risk factors for disc haemorrhages in the United Kingdom Glaucoma Treatment Study. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3535.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To identify factors associated with disc haemorrhages (DH) in the United Kingdom Glaucoma Treatment Study.

Methods : During 11 planned visits (24 months), 516 participants (258 placebo, 258 latanoprost) underwent fundus photography and HRT3 scanning. Scans were graded as DH+ or DH- masked to treatment allocation and participant characteristics. Variables from the eye with the worst VF were used. Systemic drugs and comorbidities were analysed from baseline data. Logistic and linear regressions accounting for number of visits with imaging were used to identify risk factors for DH+ participants (at least one DH in any eye and any visit), bilateral DH+ participants (DHs in right and left eye at the same or different visits), and number of DH+ visits among the DH+ participants (percentage of DH+ visits per patient). Variables previously described, biologically plausible, or with p-value < 0.20 in the univariate analysis were used in the multivariable analysis to predict i) DH+ participants, ii) bilateral DH+ participants and iii) percentage DH+ visits.

Results : Among the 516 participants, 55 (10.7%) did not attend any follow-up visits, and imaging of the optic nerve was not acquired. The mean (SD) number of visits with imaging was 8.1 (3.6). 121 (26.2%) participants were DH+ and 18 (3.9%) bilateral DH+. Among the 121 DH+, the median (IQR) percentage of DH+ visits was 20% (12.5-44.0). In a multivariable analysis (table1), older age (OR 1.04, 95% CI 1.01-1.07, p=0.007), higher tea or coffee consumption (OR 1.15, 95% CI 1.04-1.26, p=0.006), use of selective serotonin reuptake inhibitors (SSRI) (OR 4.53, 95% CI 1.24-16.58, p=0.022), and longer axial length (OR 1.22, , 95% CI 1.00-1.47, p=0.48) were associated with higher risk of DH+, while use of calcium channel blockers (CCB) (OR 0.27, 95% CI 0.10-0.75, p=0.012) was associated with lower risk. Aspirin use was associated with higher risk of bilateral DH+ (OR 11.63, 95% CI 1.31-103.31, p=0.028). Current or previous smoking (β = -0.15, 95% CI -0.25 to -0.04, p=0.006), number of visits (β = -0.03, 95% CI -0.05 to -0.01, p=0.002), and Raynaud's (β = -0.17, 95% CI -0.32 to -0.03, p=0.003) were associated with lower risk of DH+ visits.

Conclusions : SSRI and CCB were associated with higher and lower, respectively, risk of DH+ in a participant. Variables associated with DH+ in a participant seem to be different from the variables that influence bilateral DHs or DH frequency.

This is a 2020 ARVO Annual Meeting abstract.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×